About In2Bones USA
In2Bones USA is a Healthcare company based in Memphis (United States) founded in 2014, and was acquired by CONMED in May 2022. Plating and fixation systems are developed for orthopedic applications. In2Bones USA has raised $9.6 million across 4 funding rounds from investors including CONMED. In2Bones USA offers products and services including AirSeal, BioBrace, Argo Knotless Suture Anchor, and CompleteControl Sphincterotome. Its focus areas include Life Sciences, Orthopedics, Medical Devices and Therapies. Its legal entity is CONMED Corporation.
Company details
In2bonesusa is a developer of plating and fixation systems for the orthopedic markets. Few of the companys products include compression screws, snap-off screws, NeoView DR Plates, etc for Hand and Foot. The company also develops biologics. The company received FDA 510(k) clearance for its Colink Plating System in May 2017 (K163293). The company has its operations in the USA and France. The company aims to be an environment friendly company and has develops products across multiple platforms and indications including metallic alloys, biologics, and elastomers.
- Headquarters Memphis, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website i2b-usa.com
- Social LinkedIn
- Acquired by CONMED (May 2022)
- Legal Name Conmed Corporation
Products & Services of In2Bones USA
In2Bones USA offers a comprehensive portfolio of products and services, including AirSeal, BioBrace, Argo Knotless Suture Anchor, and CompleteControl Sphincterotome.
Manages smoke and maintains pressure during laparoscopic surgeries.
Reinforces tendons and ligaments with biocomposite technology.
Adjusts tension for secure surgical repairs in orthopedics.
Facilitates cannulation to reduce procedure time in GI surgeries.
Funding Insights of In2Bones USA
In2Bones USA has successfully raised a total of $9.6M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $3.6 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.6M
- Total Rounds 4
- Last Round Series A — $3.6M
- First Round $1M
(Oct 2015)
All 4 funding rounds of In2Bones USA with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2019 | $3.6M | Series A | – | – | – |
| Jun 2017 | $1.5M | Series A | – | – | – |
| Mar 2017 | $3.5M | Series A | – | – | – |
| Oct 2015 | $1M | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in In2Bones USA
In2Bones USA has secured backing from 1 investor. Prominent investors backing the company include CONMED.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Surgical instruments are manufactured for multiple therapeutic areas. | 1987 | conmed.com | Utica, United States |
Investor details for In2Bones USA
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of In2Bones USA
25 people are tracked at In2Bones USA (8 in leadership, 17 in team).
| Name | Role | Group |
|---|---|---|
Alan Taylor | President and CEO | Leadership |
John Wells | Vice President | Leadership |
Tommy Turpin | SR. VP Operations and Corporate Compliance | Leadership |
Tanya C. | Sales Director | Leadership |
Becky Noe | Director Of Procurement | Leadership |
Jim Miller | Director Of Logistics | Leadership |
Geoffrey Frampton | Associate Director, Clinical Sales | Leadership |
Matthew Crews | Director Of Engineering | Leadership |
Tate McRoberts | Independent Sales Representative | Team |
AJ Von Bergen | Sustaining Engineer, Research and Development | Team |
Robert Buchanan | Quality Engineering Manager | Team |
Bradley Cowan | Senior Product Development Engineer | Team |
Chad McClelland | Orthopedic and Wound Care Medical Device Territory Manager | Team |
Ryan Judd | Sales Associate | Team |
Jared Siemers | AVP Sales - Western US | Team |
Rita Turner | Surgical Sales Representative | Team |
Amy Makis | Sales Specialist | Team |
Scott Needleman | Sales Representative | Team |
Marielle Ramsay | Medical Device Sales Representative | Team |
Ryan Dubas | NE Regional Sales Manager | Team |
5 more people are available in the full profile.
Complete people profiles for In2Bones USA
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of In2Bones USA
4 dated milestones of In2Bones USA across 8 years, from founding to its latest funding, stage changes and deals.
- Founded In2Bones USA is founded.
- Funding First funding round of $1.0M.
- Funding Latest funding round, Series A, of $3.6M.
- Exit Acquired by CONMED.
Top companies in Orthopedics
3 companies that operate in the same segment as In2Bones USA (Orthopedics) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Provider of high-frequency spinal cord stimulation implants | 2006 | Menlo Park, California, United States | USD 154.1 M | USD 353.08 M | 1,215 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Antibody-siRNA complexes are developed for cancer treatment. | 2012 | San Diego, California, United States | USD 142.54 M | USD 10.9 M | 391 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about In2bones Usa
Complete news archive for In2Bones USA
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about In2Bones USA
In2Bones USA was founded in 2014 and raised its 1st funding round 1 year after it was founded.
In2Bones USA is headquartered in Memphis, United States. It is registered at Memphis, Tennessee, United States.
In2Bones USA is a funded company, having raised a total of $9.6M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1M, raised on Oct 2015.
In2bonesusa is a developer of plating and fixation systems for the orthopedic markets. Few of the companys products include compression screws, snap-off screws, NeoView DR Plates, etc for Hand and Foot. The company also develops biologics. The company received FDA 510(k) clearance for its Colink Plating System in May 2017 (K163293). The company has its operations in the USA and France. The company aims to be an environment friendly company and has develops products across multiple platforms and indications including metallic alloys, biologics, and elastomers.
In2Bones USA offers AirSeal, BioBrace, Argo Knotless Suture Anchor, and CompleteControl Sphincterotome.
In2Bones USA has 1 investor. Key investors include CONMED.
In2Bones USA operates through Conmed Corporation.
Yes. In2Bones USA was acquired by CONMED in May 2022.